OMRIX BIOPHARMACEUTICALS ANNOUNCES NEW PRODUCT DEVELOPMENT PLAN.

Publication: AsiaPulse News

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2006 Asia Pulse Pty Ltd

(Full text of a statement. Contact details below.)

NEW YORK--(BUSINESS WIRE)--Sept.

29, 2006--OMRIX Biopharmaceuticals, Inc.

("OMRIX" or the "Company") (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, today announced two new strategic product development programs in anti adhesion and spine utilizing its fibrin sealant technology.

Development milestones include the submission of an IND/IDE (Investigational New Drug/Investigational Device Exemption) submission in December 2006...

Read the full article for free courtesy of your local library.